Cystic Fibrosis Foundation

Concert’s CTP-656 receives FDA Orphan designation for cystic fibrosis

Monday, January 23, 2017

Concert Pharmaceuticals has announced that the FDA has granted Orphan Drug designation for CTP-656, Concert’s next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2016, Concert initiated a phase II trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline results from the phase II trial are expected by year-end 2017.

[Read More]

Cystic Fibrosis Foundation opens research lab

Tuesday, September 20, 2016

The Cystic Fibrosis Foundation has announced the official opening of a new, one-of-a kind research facility in Lexington, Massachusetts. Operated by Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the CF Foundation, the lab is designed to identify and test potential therapies for rare and common mutations of cystic fibrosis, with the ultimate goal of bringing new treatments to people living with the disease.

[Read More]

PTC Therapeutics cuts workforce 18%

Thursday, March 24, 2016

PTC Therapeutics is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S. This reduction is part of PTC’s program intended to optimally manage operating expenses following its recent setback related to the Refuse to File letter received from the FDA for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). 

[Read More]

CFFT grants Savara Pharmaceuticals $1.7 million award

Friday, October 18, 2013

Savara Pharmaceuticals has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics(CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic fibrosis (CF) who have persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection.

[Read More]